R
Ralph B. D'Agostino
Researcher at Wake Forest University
Publications - 1336
Citations - 250792
Ralph B. D'Agostino is an academic researcher from Wake Forest University. The author has contributed to research in topics: Framingham Heart Study & Framingham Risk Score. The author has an hindex of 226, co-authored 1287 publications receiving 229636 citations. Previous affiliations of Ralph B. D'Agostino include VA Boston Healthcare System & University of Illinois at Urbana–Champaign.
Papers
More filters
Journal ArticleDOI
A comparison of logistic regression to decision-tree induction in a medical domain
TL;DR: This paper compares the performance of logistic regression to decision-tree induction in classifying patients as having acute cardiac ischemia using the database of 5773 patients originally used to develop the logistic-regression tool and test it prospectively.
Journal ArticleDOI
Regulatory effects of ferritin on angiogenesis
TL;DR: Ferritin-mediated regulation of angiogenesis represents a new angiogenic regulatory pathway, and identifies a new role for ferritin in cell biology.
Journal ArticleDOI
Benefits and Adverse Effects of Weight Loss: Observations from the Framingham Study
TL;DR: This report defined cardiovascular disease as coronary heart disease, stroke, intermittent claudication, and congestive heart failure as well as other clinically diagnosed diseases including mitral or aortic valve disease, arthritis, urinary disease, neurologic disease, and other vascular disease.
Journal ArticleDOI
Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With Hutchinson-Gilford Progeria Syndrome
Leslie B. Gordon,Leslie B. Gordon,Heather Shappell,Joseph M. Massaro,Ralph B. D'Agostino,Joan F. Brazier,Susan E. Campbell,Monica E. Kleinman,Mark W. Kieran,Mark W. Kieran +9 more
TL;DR: Among patients with HGPS, lonafarnib monotherapy, compared with no treatment, was associated with a lower mortality rate after 2.2 years of follow-up, and the association of monotherapy using the protein farnesyltransferase inhibitor lonfarnib with mortality rate was evaluated.
Journal ArticleDOI
Insulin Sensitivity, Insulinemia, and Coronary Artery Disease The Insulin Resistance Atherosclerosis Study
Marian Rewers,Daniel J. Zaccaro,Ralph B. D'Agostino,Steven M. Haffner,Mohammed F. Saad,Joe V. Selby,Richard N. Bergman,Peter J. Savage +7 more
TL;DR: In this paper, the authors evaluated whether low insulin sensitivity measured using a modified frequently sampled intravenous glucose tolerance test with minimal model analysis is associated with coronary artery disease (CAD) independent of other cardiovascular risk factors.